Endocrine Abstracts

The aim of the study: Laparoscopic sleeve gastroectomy is now the gold standard for bariatric surgery for the treatment of obesity and metabolic syndrome. Laparoscopic gastroplasty is a relatively innovative procedure that has recently been used throughout the world. The purpose of the study was to assess the perioperative safety and outcome of procedures in 2 years.

Materials and methods: Sixty two patients with a body mass index of 35 kg/m² to 50 kg/m² who were undergoing surgical barrier intervention. Laparoscopic gastroplasty was performed for thirty-eight patients, and 24 patients chose gastro-enteromatous sleeve. Patients were monitored for 2 years after surgery. During this period, both groups studied the percentage of loss of overweight, early and late complications, and improved comorbid conditions associated with obesity and nutritional disorders.

Results: Both groups did not have fatalities, and there was no significant difference in the results of early and late morbidity in both groups (11% after laparoscopic gastroplasty and 12.5% after sleeve gastroectomy). Losing weight was much better after sleeve gastroectomy. During 2 years of observation, the percentage of loss of overweight reached 46% after laparoscopic gastroplasty and 62% after sleeve gastroectomy. There was no significant difference in the overall improvement of concomitant diseases. Nutrient deficits were similar in both groups, with the exception of vitamin B12 deficiency, which was more common after sleeve gastroectomy.

Conclusions: Sleeve gastroectomy and laparoscopic gastroplasty are equally safe and effective for the improvement of concomitant diseases. Sleeve gastrectomy has a better result of overweight loss, whereas laparoscopic gastroplasty is associated with fewer postoperative metabolic deficiencies, without correction. The use of laparoscopic gastroplasty requires additional research to prove the reliability and metabolic efficiency of the new procedure.